WHO ICTRP trial
Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor…
NL-OMON45455 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON45455 |
|---|---|
| Public title | Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial (HoT-PE) |
| Scientific title | Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial (HoT-PE) - HoT-PE |
| Primary sponsor | University Medical Centre Johannes Gutenberg-University Mainz |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Observational invasive |
| Phase | 4 |
| Countries | The Netherlands |
| Conditions | Low risk acute pulmonary embolism;10037454;Low risk acute pulmonary embolism |
| Interventions | ;muti-center;pulmonary embolism (PE);single-arm |
| Registration date | Oct 8, 2018 |
| Target size | 143 |
| Secondary IDs | 2013-001657-28;NL58418.101.16 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: